Education
About Us
Working with TipRanks
Follow Us
Diaceutics (GB:DXRX)
LSE:DXRX
DXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range95.00p - 151.00p
Previous CloseN/A
Volume29.93K
Average Volume (3M)62.03K
Market Cap
$100.11M
Enterprise Value92.48M
Total Cash (Recent Filing)£2.07M
Total Debt (Recent Filing)£3.75M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Sep 15, 2025EPS Estimate
2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,798,380
10 Day Avg. Volume43,459
30 Day Avg. Volume62,026
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.06
Price to Cash Flow (P/CF)46.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$210.07Price Target Upside77.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Diaceutics News
PremiumCompany Announcements
Diaceutics PLC Enhances Employee Shareholding with New Share Incentive Plan
PremiumCompany Announcements
Diaceutics Enhances PMx Contract with Partner Therapeutics for BIZENGRI®
PremiumCompany Announcements
Diaceutics PLC Aligns Employee Incentives with Share Awards
PremiumCompany Announcements
Diaceutics Director Increases Stake Signaling Confidence in Company Growth
PremiumCompany Announcements
Diaceutics Enhances Employee Incentive Program with Share AwardsPremiumCompany Announcements
Diaceutics Reports Strong FY 2024 Growth and Positive OutlookPremiumCompany Announcements
Diaceutics Opens New US Headquarters to Boost Market Presence---
Bulls Say, Bears Say
Bulls Say
Client BaseDiaceutics now works with 18 of the top 20 global pharma companies across 56 therapeutic brands, highlighting significant customer and brand wins.
ContractsDiaceutics has successfully renegotiated its first PMx contract with the new commercial licensee, which is worth £4.5m in recurring service revenues.
EarningsDiaceutics has delivered yet another year of impressive organic growth with FY24 revenues increasing 36% to £32.2m, c.7% ahead of market expectations.
Bears Say
Order BookThe year-end order book was down 11% to £24.9m compared to the previous year, and recurring revenues were broadly flat at 55%.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.10% Insiders
―
Mutual Funds
― Other Institutional Investors
99.90% Public Companies and
Individual Investors
DXRX FAQ
What was Diaceutics’s price range in the past 12 months?
Diaceutics lowest share price was 95.00p and its highest was 151.00p in the past 12 months.
What is Diaceutics’s market cap?
Diaceutics’s market cap is $100.11M.
When is Diaceutics’s upcoming earnings report date?
Diaceutics’s upcoming earnings report date is Sep 15, 2025 which is in 144 days.
How were Diaceutics’s earnings last quarter?
Diaceutics released its earnings results on Mar 25, 2025. The company reported 0.021p earnings per share for the quarter, the consensus estimate of 0.021p by 0p.
Is Diaceutics overvalued?
According to Wall Street analysts Diaceutics’s price is currently Undervalued.
Does Diaceutics pay dividends?
Diaceutics does not currently pay dividends.
What is Diaceutics’s EPS estimate?
Diaceutics’s EPS estimate is 2.1.
How many shares outstanding does Diaceutics have?
Diaceutics has 84,798,380 shares outstanding.
What happened to Diaceutics’s price movement after its last earnings report?
Diaceutics reported an EPS of 0.021p in its last earnings report, expectations of 0.021p. Following the earnings report the stock price went up 0.398%.
Which hedge fund is a major shareholder of Diaceutics?
Currently, no hedge funds are holding shares in GB:DXRX
---
Company Description
Diaceutics
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
---
DXRX Stock 12 Month Forecast
Average Price Target
210.07p
▲(77.28% Upside)
Technical Analysis
Best Analysts Covering DXRX
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
+4.30%
reiterated a buy rating 30 days ago
Copying Christian Glennie's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of +4.30% per trade.
---